Discover the most comprehensive and reliable drug information source with AHFS Drug Information? 2024, a trusted choice on the Doody's Core Titles List from 2020 to 2023. This essential reference is your all-in-one solution for evidence-based therapeutic guidelines and off-label uses, ensuring you have the information you need to protect your patients and enhance your practice. The 2024 edition is thoroughly updated and expanded, featuring over 97,000 references and insights from leading experts. Stay ahead with the latest clinical perspectives, including therapy placement discussions and guideline recommendations. Dive into in-depth coverage of specialty medications for complex, chronic conditions that demand precise handling, monitoring, and dosage adjustments. Explore contemporary topics such as new treatments and vaccines for RSV, safety considerations for GLP-1 agonists, novel orphan drugs, and biosimilars. Gain knowledge on emerging gene therapies and updated vaccine monographs, including pneumococcal, rabies, and RSV vaccines. AHFS DI 2024 also provides crucial information on off-label uses, long-term clinical data, MedWatch alerts, Standardize4Safety initiatives, REMS data, and targeted FDA updates. Additionally, it introduces content on over 175 new molecular entities and therapeutic biological products, with significant revisions on nearly 190 medications. Learn more and order here.
|